The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)
Randomised, quadruple-blind, factorial trial (n=150) comparing S-ketamine 0.25 mg/kg and ketamine 0.5 mg/kg versus propofol+saline during ECT in adults with depressive disorders to evaluate short-term efficacy and safety.
Details
This randomised, quadruple-blind, factorial study (n=150) evaluates whether adjunctive intravenous S-ketamine (0.25 mg/kg) or ketamine (0.5 mg/kg), given with propofol anaesthesia, improves short-term antidepressant outcomes and safety during routine ECT for adults with depressive disorders.
Primary outcomes focus on short-term efficacy and safety; secondary assessments include cognitive effects, adverse events, and measures relevant to suicide risk and relapse.
Interventions compare three arms: propofol+saline (placebo comparator), propofol+ketamine (0.5 mg/kg), and propofol+S-ketamine (0.25 mg/kg), administered as IV bolus infusions prior to ECT sessions.